

EFPIA **Manifesto** for an Integrated Life Sciences Strategy in Europe



Economic recession and austerity policies have impacted Europe's healthcare systems and compromised citizens' health status, while deepening access inequalities across the EU. Health is a key concern for Europe and its citizens, both in terms of societal wellbeing and economic prosperity. The healthcare sector is strongly driven by innovation, which impacts positively on health outcomes and serves as a key driver of economic growth.

EFPIA believes in a new generation of multi-stakeholder partnerships and collaborative solutions to target the EU's health and competitiveness challenges. A new European Life Sciences Strategy will be vital to achieving the objectives of Europe 2020 and beyond.

To build a vibrant European healthcare ecosystem, EFPIA calls on European leaders to break down silos and agree on a comprehensive strategy for life sciences, based on three separate but highly interdependent pillars:



Improve health outcomes & remove inequalities to better patient benefits

As more EU citizens live more years with some form of disability or illness, societies must devote more attention to reducing the prevalence of disease and increasing patients' functioning in later years. We need to establish EU-wide standards for integrated care and pathway management, based on standardised measurements of clinical outcomes.

More systematic use of health records with appropriate privacy and ethical controls will help speed up the development and deployment of new medicines. It is important that the EU continues to allow access to health data for research, and develops standards for data capture and data exchange.

The widespread use of mobile-health tools presents an opportunity to improve adherence, promote self-management, and collect patient-reported adverse events and outcomes. The EU needs to make sure that the regulatory framework allows creative solutions to be developed.

In the interests of improved and equal access for all patients in Europe, the EU should encourage the adoption of new voluntary measures to ensure that the single market results in fair prices, based on ability to pay. The EU should encourage Member States to take reasonable measures to ensure security of medicines supply on their territory, and encourage new access solutions, while minimising the impact on price referencing beyond national borders.



Support sustainable & predictable healthcare systems to speed access to medicines

The research-based pharmaceutical industry calls for governments, payers, and industry to develop Growth and Stability agreements, where they are not in place already, for budget allocation on medicines across Europe with an objective of securing optimal access to innovative medicines. This will help improve predictability for all parties in the healthcare ecosystem.

Despite having one regulatory system for the approval of new medicines, inequalities in access to medicines remain, since decisions on pricing and reimbursement of medicines are more fragmented than ever and are taking longer. The emerging EU collaboration on Health Technology Assessment should help overcome this fragmentation and bring convergence in the assessment of therapeutic added value of new medicines and patient outcomes.



Build a thriving innovative life sciences sector to promote European competitiveness

It is time for Europe to recommit to excellence and create an environment that encourages innovation and attracts high quality investment. EU Member States have consistently missed their three per cent R&D target agreed as part of the Lisbon agenda. The Innovative Medicines Initiative is a great example of how industry can work with EU and academia to advance science. But we need to go further. Europe must regain scientific leadership by stronger

coordination of nationally fragmented policies under a world class, pan-European R&D agenda. The EU should pull together nationally funded groups in a new network. The network should adopt a holistic and long-term perspective on the health challenges facing Europe, foster public-private partnerships on open innovation within biomedical research, and champion regulatory reform to enable and reward innovation.

NOW IS THE TIME TO LOOK AHEAD.

To return to prosperity and preserve its identity, Europe must emerge from the crisis as a highly competitive economy, grounded in a skilled workforce, a healthy population, and a sustainable social model. Any challenges that stand in the way can surely be overcome with a collaborative effort.

efpia

European Federation of Pharmaceutical
Industries and Associations

EFPIA Brussels Office

Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels * Belgium

Tel: +32 (0)2 626 25 55

Fax: +32 (0)2 626 25 66

info@efpia.eu * www.efpia.eu